Core Insights - The company reported a revenue of 2.82 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 2.67% [1] - Gross profit reached 2.199 billion RMB, up 10.47% year-on-year, while net profit attributable to shareholders was 390 million RMB, a 0.99% increase [1] - The company invested approximately 995 million RMB in R&D, an increase of about 170 million RMB compared to the same period last year, focusing on innovative R&D projects to accelerate transformation [1] Group Performance - The overseas product sales revenue was approximately 40.6 million RMB, with profits from overseas products more than doubling compared to the same period last year, driven by the company's international strategy and increased sales in the U.S. market [1] - As of August 22, 2025, the company has successfully launched six products (covering 25 indications) in multiple countries, including China, the U.S., Europe, and others, benefiting over 850,000 patients globally [2] - The product "Hanshu" for extensive-stage small cell lung cancer was approved for first-line treatment in the EU in February 2025, marking the company's second product approved in the EU [2] - The biosimilar HLX14 received a positive opinion from the European Medicines Agency (EMA) in July 2025, paving the way for its market entry in broader overseas markets [2]
复宏汉霖(02696)发布中期业绩 股东应占溢利3.9亿元 同比增加0.99% 海外产品利润同比实现超2倍突破增长